Chaucanez-Bastidas YK, Ortiz-Morales D, Pasquel-García VP, Martínez-Ávalos AB

Idioma: Español
Referencias bibliográficas: 65
Paginas: 456-463
Archivo PDF: 943.90 Kb.

RESUMEN

El carcinoma tímico es una neoplasia poco frecuente en la población pediátrica. El diagnóstico diferencial se realiza con tumores mediastinales. Generalmente las manifestaciones clínicas se deben a obstrucción de la vía aérea. El tratamiento incluye cirugía, quimioterapia y radioterapia. Los esquemas de tratamiento, especialmente la quimioterapia, es motivo de controversia en niños y la mayoría de los protocolos se basan en la experiencia obtenida de los adultos. El pronóstico es malo, con pocas posibilidades de curación, depende del estadio según la clasificación de Masaoka y de la posibilidad de resección quirúrgica.
En este informe se describen dos casos de carcinoma tímico en niños: uno de 12 años cuya afección se inició con cianosis e hipercalcemia y en una paciente de 14 años en quien empezó con tos y dolor torácico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Hasserjian RP, Strobel P, Marx A. Pathology of thymic tumors. Semin Thorac Cardiovasc Surg 2004;17:2–11.

2. de Jong WK, Blauwgeers JL, Schaapveld M, et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008;441:123–130.

3. Yaris N, Nas Y, Cobanoglu U, Yavuz MN. Thymic carcinoma in children. Pediatr Blood Cancer 2006;47:224-227.

4. Smit EF. Thymic malignancies. Ann Oncol 2008;19:309–12.

5. Ramon Cajal S, Suster S. Primary thymic epithelial neoplasms in children. Am J Surg Pathol 1991;15:466-474.

6. Okomura M, Schinichiro M, Fujii Y, et al. Clinical and functional significance of WHO classification on human thymic epithelial neoplasm: A study of 146 consecutive tumors. Am J Surg Pathol 2001;25:103–110.

7. Rios A, Torres J, Galindo PJ, et al. Prognostic factors in thymic epithelial neoplasms. Eur J Cardiothorac Surg 2002;21:307–313.

8. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: A clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95:420–429.

9. Stachowicz-Stencel T, Bien E, Balcerska A, Godzinski J, Synakiewicz A, Madziara W, et al. Thymic carcinoma in children: a report from the Polish Paediatric Rare Tumours Study. Pediatr Blood Cancer 2010;54:916-920.

10. Carretto E, Inserra A, Ferrari A, et al. Epithelial thymic tumours in paediatric age: a report from the TREP Project. Orphanet J Rare Dis 2011;6:28–35.

11. Suster S, Moran CA. Thymoma classification: current status and future trends. Am J Clin Pathol 2006;125:542–554.

12. Hishima T, Fukayama M, Fujisawa M, et al. CD5 expression in thymic carcinoma. Am J Pathol 1994;145:268-275.

13. Suster S. Thymic carcinoma: update of current diagnostic criteria and histologic types. Semin Diagn Pathol 2005;22:198–212.

14. Rosai J, Sobin LH. Histological typing of tumours of the thymus. International histological classification of tumours, 2nd edition. New York: Springer, 1999.

15. Schmidt-Wolf IG, Rockstroh JK, Schuller H, et al. Malignant thymoma: Current status of classification and multimodality treatment. Ann Hematol 2003;82:69–76.

16. Liu, H, Hsu W, Chen Y, et al. Primary thymic carcinoma. Ann Thorac Surg 2002;15:1076–81.

17. Niehues T, Harms D, Jurgens H, et al. Treatment of pediatric malignant thymoma: Long-term remission in a 14-year-old boy with EBV-associated thymic carcinoma by aggressive, combined modality treatment. Med Pediatr Oncol 1996;26:419–424.

18. Ihan I, Kutluk T, Gogus S, et al. Hypertrophic pulmonary osteoarthropathy in child with carcinoma: An unusual presentation in childhood. Med Pediatr Oncol 1994;23:140–143.

19. Di-Cataldo A, Villari L, Milone P, et al. Thymic carcinoma, systemic lupus erytematosus, and hypertrophic pulmonary osteoarthropathy in an 11-year-old boy: A novel association. Pediatr Hematol Oncol 2000;17:701–706.

20. Sung YM, Lee KS, Kim BT, et al. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med 2006;47:1628–34.

21. Hartmann CA, Roth C, Mink C, et al. Thymic carcinoma: Report of five cases and review of the literature. J Cancer Res Clin Oncol 1990;116:69-82.

22. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002;94:624–632.

23. Masaoka A, Yamakawa Y, Niwa H, et al. Thymectomy and malignancy. Eur J Cardiothoracic Surg 1994;8:251. 24. Suster S, Moran CA. Thymic carcinoma: Spectrum of differentiation and histologic types. Pathology 1998;30:111–122.

24. Muller-Hermelink HK, Marino M, Palestro G, et al. Immunohistological evidences of cortical and medullary differentiation in thymoma. Virchows Arch A Pathol Anat Histopathol 1985;408:143–161.

25. Kondo K, Yasumasa M. Therapy for thymic epithelial tumors: A clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003;76:878-885.

26. Okereke IC, Kesler KA, Freeman RK, et al. Thymic carcinoma: outcomes after surgical resection. Ann Thorac Surg 2012;93:1668-72.

27. Venuta F, Rendina EA, Longo F, et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 2003;76:1866–1872.

28. Rajan A, Giaccone G. Treatment of advanced thymoma and thymic carcinoma. Curr Treat Options Oncol 2008;9:277–287.

29. Yasuda M, Hanagiri T, Oka S, Uramoto H, Takenoyama M, yasumoto K. Results of a surgical resection for patients with thymic carcinoma. Scandinavian Journal of Surgery 2011;100:159-163.

30. Dhall G, Ginsburg HB, Bodenstein L, Fefferman NR, Greco MA, Chang MW, Gardner S. Thymoma in children: report of two cases and review of literature. J Pediatr Hematol Oncol 2004;26:681-685.

31. Liang X, Lovell MA, Capocelli KE, Albano EA, Birch S, Keating AK, Graham DK. Thymoma in children: report of 2 cases and review of the literature. Pediatr Develop Pathol 2010;13:202-208.

32. Giaccone G. Treatment of malignant thymoma. Curr Opin Oncol 2005;17:140–146.

33. Papadopoulos K, Thomas CR. Current chemotherapy options for thymic epithelial neoplasms. Expert Opin Pharmacother 2005;6:1169–1177.

34. Wright, C. D. Extended resections for thymic malignancies. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2010;5(10) Suppl 4:S344-7.

35. Ettinger D, Wallace A, Bepler G, Blum M, Chang A, Cheney R, Chirieac L, et al. Thymic Malignancies. Journal of the National Comprehensive Cancer Network. 2010;8:1302-1315.

36. Rena O, Papalia E, Oliaro A, et al. Does adjuvant radiation therapy improve disease-free survival in completely resected Masaoka stage II thymoma? Eur J Cardiothoracic Surg 2007;31:109–113.

37. Onuki T, Ishikawa S, Yamamoto T, et al. Pathologic radioresponse of preoperatively irradiated invasive thymomas. J Thorac Oncol 2008;3:270–276.

38. Odriozola JM, Muguruza-Trueba I, Muñoz-Molina G, Cabañero-Sánchez A, Saldaña-Garrido D, Lago-Viguera J. Carcinoma tímico. Tratamiento quirúrgico tras quimioterapia neoadyuvante. Neumologiía y cirugía de tórax 2006;65(4):170-173.

39. Fuller CD, Ramahi E, Aherne N, Eng T, Thomas Jr C. Radiotherapy for thymic neoplasms. Journal of thoracic oncology. Official publication of the International Association for the Study of Lung Cancer 2010 5, No. 1004: S327.

40. Wright CD, Choi NC, Wain JC, et al. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 2008;85:385–389.

41. Nonaka T, Tamami Y, Higuchi K, et al. The role of radiotherapy for thymic carcinoma. Jpn J Clin Oncol 2004;34:722–726.

42. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemo-therapy for unresectable malignant thymomas: Final report. Lung Cancer 2004;44:369–379.

43. Ogawa K, Toita T, Uno T, Fuwa N, Kakinohana Y, Kamata M, Koja K, Kinjo T, Adachi G, Murayama S. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer 2002;94(12):3115-9.

44. Eng TY, Thomas Jr C. Radiation therapy in the management of thymic tumors. En Seminars in thoracic and cardiovascular surgery, No 1, WB Saunders. 2005;17:32-40.

45. Yano M, Sasaki H, Yokomyama T, et al. Thymic carcinoma: 30 Cases at a single institution. J Thorac Oncol 2008;3:265-269.

46. Evans T, Lynch T. Role of chemotherapy in the management of advanced thymic tumors. Semin Thorac Cardiovasc Surg 2005;17:41–50.

47. Lucchi M, Ambrogi MC, Duranti L, Basolo F, Fontanini G, Angeletti CA, Mussi A. Advanced stage thymomas and thymic carcinomas: results of multimodality treatment. Ann Thorac Surg 2005;79:1840-1844.

48. Carlson RW, Dorfman RF, Sikic BI. Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin and etoposide chemotherapy. Cancer 1990;66:2092–4.

49. Yoh, K, Goto, K, Ishii, G, et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 2003;98,926-931.

50. Yokoi K, Matsuguma H, Nakahara R, et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2007;2:73–78.

51. Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabro F, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991;68:30–3.

52. Furugen M, Sekine I, Tsuta K, et al. Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer. Jpn J Clin Oncol 2011;41:1013-1016.

53. Maruyama R, Suemitsu R, Okamoto T, Kojo M, Aoki Y, Wataya H, et al. Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients. Oncology 2006;70:325–9.

54. Igawa S, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Naito T, et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 2010;67:194–7.

55. Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011;29:2060–5.

56. Morio A, Nakahara K, Ohse Y, et al. Efficacy of induction chemoradiotherapy in thymic cancer: report of a successful case and review of the literature. Int J Clin Oncol 2002;7:201-204.

57. Shintani Y, Ohta M, Hazama K, et al. Thymic carcinoma successfully resected with superior vena cava after chemoradiotherapy. Jpn J Thorac Cardiovasc Surg 2001;49:712-721.

58. Lucchi M, Mussi A, Basolo F, Ambrogi MC, Fontani G, Angeletti CA. The multimodality treatment of thymic carcinoma. European Journal of Cardiothoracic Surgery 2001;19:566-569.

59. Kurup A, Loehrer PJ Sr. Thymoma and thymic carcinoma: therapeutic approaches. Clin Lung Cancer 2004;6(1):28-32.

60. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625–2626.

61. Pan CC, Chen PC, Chiang H et al. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004;202:375–381.

62. Wright CD, Wain JC, Wong DR, Donhaue DM, Gaissert HA, Grillo HC, Mathisen DJ. Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology and size. J Thorac Cardiovasc Surg 2005;130:1413-1421.

63. Eng YH, Chong JW, Li MS, Hui CC. Post-operative radiotherapy in thymic carcinoma: treatment results and prognosis factors. Int J Radiation Oncology Biol Phys 2002;52(3):801-805.

64. Chung DA. Thymic carcinoma: Analysis of nineteen clinicopathological studies. Thorac Cardiov Surg 2000;48:114–119.

65. Detterbeck F, Parsons A. Thymic tumors. Ann Thorac Surg 2004;77(5):1860-69.